JPWO2020142742A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020142742A5 JPWO2020142742A5 JP2021538976A JP2021538976A JPWO2020142742A5 JP WO2020142742 A5 JPWO2020142742 A5 JP WO2020142742A5 JP 2021538976 A JP2021538976 A JP 2021538976A JP 2021538976 A JP2021538976 A JP 2021538976A JP WO2020142742 A5 JPWO2020142742 A5 JP WO2020142742A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- pharmaceutically acceptable
- acceptable salt
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 75
- 239000011780 sodium chloride Substances 0.000 claims description 75
- 125000003118 aryl group Chemical group 0.000 claims description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims description 66
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 46
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 10
- 210000004027 cells Anatomy 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims description 8
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 102000003973 fibroblast growth factor 21 Human genes 0.000 claims description 6
- 108090000376 fibroblast growth factor 21 Proteins 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000001404 mediated Effects 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 108010028924 PPAR alpha Proteins 0.000 claims description 4
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 4
- 210000002381 Plasma Anatomy 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 201000009030 carcinoma Diseases 0.000 claims description 3
- 230000001684 chronic Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000007838 tissue remodeling Effects 0.000 claims description 3
- -1 -OH Chemical group 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000009956 Adenocarcinoma Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 2
- 210000000845 Cartilage Anatomy 0.000 claims description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- 210000002808 Connective Tissue Anatomy 0.000 claims description 2
- 206010011401 Crohn's disease Diseases 0.000 claims description 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 2
- 102000005593 Endopeptidases Human genes 0.000 claims description 2
- 108010059378 Endopeptidases Proteins 0.000 claims description 2
- 102000018389 Exopeptidases Human genes 0.000 claims description 2
- 108010091443 Exopeptidases Proteins 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002297 Fenofibrate Drugs 0.000 claims description 2
- 210000001117 Keloid Anatomy 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 230000003143 atherosclerotic Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 201000011231 colorectal cancer Diseases 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 2
- 230000004059 degradation Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing Effects 0.000 claims description 2
- 201000008808 fibrosarcoma Diseases 0.000 claims description 2
- 230000003176 fibrotic Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 230000002496 gastric Effects 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001394 metastastic Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 description 7
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788722P | 2019-01-04 | 2019-01-04 | |
| US62/788,722 | 2019-01-04 | ||
| US201962863853P | 2019-06-19 | 2019-06-19 | |
| US62/863,853 | 2019-06-19 | ||
| PCT/US2020/012260 WO2020142742A1 (en) | 2019-01-04 | 2020-01-03 | Inhibitors of fibroblast activation protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516555A JP2022516555A (ja) | 2022-02-28 |
| JPWO2020142742A5 true JPWO2020142742A5 (de) | 2023-01-11 |
Family
ID=71404153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538976A Pending JP2022516555A (ja) | 2019-01-04 | 2020-01-03 | 線維芽細胞活性化タンパク質の阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200216417A1 (de) |
| EP (1) | EP3906024A4 (de) |
| JP (1) | JP2022516555A (de) |
| KR (1) | KR20210113634A (de) |
| CN (1) | CN114126597A (de) |
| AU (1) | AU2020204714A1 (de) |
| BR (1) | BR112021011861A2 (de) |
| CA (1) | CA3124525A1 (de) |
| CL (1) | CL2021001739A1 (de) |
| IL (1) | IL284434A (de) |
| MX (1) | MX2021007948A (de) |
| SG (1) | SG11202106399XA (de) |
| WO (1) | WO2020142742A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972577T3 (es) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP) |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006246719A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CN101232873A (zh) * | 2005-08-11 | 2008-07-30 | 霍夫曼-拉罗奇有限公司 | 含有dpp-iv抑制剂的药物组合物 |
| US9346814B2 (en) * | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
| AU2018386298B2 (en) * | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| US11504364B2 (en) * | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
-
2020
- 2020-01-03 CA CA3124525A patent/CA3124525A1/en active Pending
- 2020-01-03 MX MX2021007948A patent/MX2021007948A/es unknown
- 2020-01-03 EP EP20735966.2A patent/EP3906024A4/de not_active Withdrawn
- 2020-01-03 WO PCT/US2020/012260 patent/WO2020142742A1/en unknown
- 2020-01-03 KR KR1020217024699A patent/KR20210113634A/ko unknown
- 2020-01-03 CN CN202080007971.2A patent/CN114126597A/zh active Pending
- 2020-01-03 JP JP2021538976A patent/JP2022516555A/ja active Pending
- 2020-01-03 BR BR112021011861-6A patent/BR112021011861A2/pt unknown
- 2020-01-03 US US16/734,214 patent/US20200216417A1/en not_active Abandoned
- 2020-01-03 SG SG11202106399XA patent/SG11202106399XA/en unknown
- 2020-01-03 AU AU2020204714A patent/AU2020204714A1/en not_active Abandoned
-
2021
- 2021-06-28 IL IL284434A patent/IL284434A/en unknown
- 2021-06-29 CL CL2021001739A patent/CL2021001739A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970705393A (ko) | 암 치료를 위한 화합물 및 방법(compounds and methods for the treatment of cancer) | |
| RU2306933C2 (ru) | Улучшенная схема применения противоопухолевого соединения в терапии рака | |
| RU2010123884A (ru) | Лечение рака молочной железы с помощью ингибитора parp отдельно или в комбинации с противоопухолевыми средствами | |
| JP2005500300A5 (de) | ||
| HU223732B1 (hu) | Taxoidok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| JPH10152454A (ja) | 生物学的に活性なカルボン酸エステル類 | |
| AU2018252003A1 (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| WO2012142615A2 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| CA2797182A1 (en) | Methods of enhancing antibody-dependent cellular cytotoxicity | |
| JPWO2020142742A5 (de) | ||
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| JPWO2020132661A5 (de) | ||
| CN1073106C (zh) | 新的紫杉化合物,其制备方法及其药物组合物 | |
| NZ530572A (en) | Combinations comprising bisphosphonate and epothilones, and pharmaceutical uses thereof | |
| WO2005049030A1 (en) | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer | |
| WO2020187188A1 (zh) | 喹啉衍生物及免疫调节剂联合在制备抗肿瘤药物中的应用 | |
| RU2428188C2 (ru) | Комбинация, содержащая n-(3-метокси-5-метилпиразин-2-ил)-2-(4-[1,3,4-оксадиазол-2-ил]фенил)пиридин-3-сульфонамид и антимитотическое средство, для лечения злокачественного новообразования | |
| JP2013525290A5 (de) | ||
| JP2002326936A (ja) | 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強 | |
| JPH07506586A (ja) | 新規タキサン誘導体，それらの製造，およびそれらを含む組成物 | |
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака | |
| HUT77930A (hu) | Új taxoidok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| RU2021121980A (ru) | Ингибиторы белка активации фибробластов | |
| EP1050302A1 (de) | Verfahren zur Behandlung von abnormaler Zellproliferation im Gehirn |